Day Two – 25 March 2010
Chair: Dr. Keith Schlagbauer, Director of Healthcare Consulting, Europe, Frost & Sullivan
09:00 – 09:40 The latest New Supplier Selection Strategies that Minimise Risk
• Reviewing the key factors in the supplier selection process
• Successfully increasing the transparency of your supply chain
• Supplier consolidation – does it decrease risk?
• Supplier consolidation – should it be horizontal or by function?
• Exploring the latest audit procedures and requirements that minimise surprises
Dennis Seagle, Business Director, ICB, Boehringer Ingelheim
09:40 – 10:20 The ‘Emerging’ Emerging Markets – Where, When and at What Cost?
• Key regional competencies for Pharma manufacturing and API supply outside of India and China
• Comparing the expertise of suppliers and manufactures in Brazil, Russia, Vietnam, Indonesia, Bangladesh, and other markets
• Deal making to take advantage of cost benefits in new markets
• Lessons learned from sourcing from India and China
Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters
10:20 – 11:00 Evaluating the Revival of European Manufacturing and API Production
• How does the EU compare to emerging markets? Cost, quality and reliability
• Reviewing the pros and cons of a European supply base
• Charting the re-emergence of the competitive European API suppliers
Dr. Keith Schlagbauer, Director of Healthcare Consulting, Europe, Frost & Sullivan
11:00 – 11:30 Refreshment & Networking
12:00 - 13:00 Roundtables
Roundtable 1 Successfully Sourcing from India –
past experiences – who to select and who to avoid
Hosted by: Dr. Patrice Talaga, Director,
Chemistry Outsourcing, UCB Pharma & Stefan Bertram, Sr Account Manager, Industrial Customer Business, Boehringer Ingelheim
| Roundtable 2 Successfully Sourcing from China – past experiences – who to select and who to avoid
Hosted by: Andrew Anderson, API SS&P
Sourcing Lead, Pfizer
|
Roundtable 3 Successfully Sourcing from Europe –
past experiences – who to select and who to avoid
Hosted by: Dr. Roberto Margarita,
Business Development Director, Bristol-Myers Squibb & Silvia Di Benedetto, Contract Manufacturing Division - Europe, F.I.S. - Fabbrica Italiana Sintetici | Roundtable 4 The Best of the Rest –
past experiences – who to select and who to avoid
Hosted by: Dr. Keith Schlagbauer, Director of Healthcare Consulting, Europe, Frost & Sullivan |
12:30 – 13:30 Networking Lunch
13:30 – 14:10 Protecting the Crown Jewels: Minimising IP Risks When Outsourcing
• Evaluating the key IP risks of outsourcing API development and manufacture
• Formulating an effective IP protection and control strategy
I• ncorporating your IP strategy in contractual arrangements
• Avoiding FTO problems through robust contractual outsourcing agreements
• Enforcing the contract: practical tips on making your IP strategy effective
Christoph de Coster, Attorney in Law & Tim Worden, Partner, Taylor Wessing LLP
14:10 – 14.50 An Issue of Quality – How Can You Maintain Standards When Sourcing Globally?
• Quality assurance systems that guarantee traceability processes and minimise risk
• Evaluating new suppliers ability to meet your supply and quality requirements
• Reviewing the quality and safety issues connected to bulk drug sourcing
Eric Hilton, Director, FDAS – Food & Drug Analytical Services
14:50 – 15.20 Refreshment & Networking
15:20 – 16:00 Closing Panel Debate – PharmaSource10 – Any Questions?
• Evaluating the risks – will emerging market sourcing come back to haunt Big Pharma?
• Are local sourcing centres the key to LCCS success
• What drives Big Pharma to outsource production?
• When should you simply not outsource? Are there sacred cows that must be kept at all costs?
• Can you successfully optimise your value chain and maintain the security of your supply chain?
Speakers: A selection of speakers from across both days of the conference
